BioCentury
ARTICLE | Company News

Biovitrum in deal for three Amgen drugs

September 16, 2008 1:45 AM UTC

Biovitrum (SSE:BVT) will acquire marketed products Kepivance palifermin and Stemgen ancestim from Amgen (NASDAQ:AMGN). The deal also includes an exclusive, worldwide license to Amgen's Kineret anakinra for rheumatoid arthritis (RA). Amgen will receive about $130 million up front, comprising $110 million in cash and $20 million in Biovitrum stock. Amgen also is eligible for a single sales milestone payment each for Kineret and Kepivance, and royalties on additional developed products that are based on Kineret. Combined sales of the three products were about $70 million in 2007. ...